Dexamethasone trial results confirm COVID-19 benefits but also risks

WASHINGTON, July 18 (AFP) - The keenly-awaited full results from a UK trial of the steroid dexamethasone were published Friday, confirming its life- saving benefits for COVID-19 patients on ventilators but suggesting it may cause harm if given too early.

A total of 2,104 hospitalized patients were assigned to receive six milligram daily doses of the medicine for up to 10 days.